These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 18076768)

  • 21. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    Xiang SH; Kwong PD; Gupta R; Rizzuto CD; Casper DJ; Wyatt R; Wang L; Hendrickson WA; Doyle ML; Sodroski J
    J Virol; 2002 Oct; 76(19):9888-99. PubMed ID: 12208966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.
    Joshi A; Lee RT; Mohl J; Sedano M; Khong WX; Ng OT; Maurer-Stroh S; Garg H
    J Biol Chem; 2014 Jan; 289(5):2497-514. PubMed ID: 24265318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
    Fernàndez G; Llano A; Esgleas M; Clotet B; Esté JA; Martínez MA
    J Gen Virol; 2006 May; 87(Pt 5):1285-1294. PubMed ID: 16603531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome.
    Gray L; Sterjovski J; Churchill M; Ellery P; Nasr N; Lewin SR; Crowe SM; Wesselingh SL; Cunningham AL; Gorry PR
    Virology; 2005 Jul; 337(2):384-98. PubMed ID: 15916792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic Correlates of HIV-1 Macrophage Tropism.
    Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
    J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
    Reeves JD; Miamidian JL; Biscone MJ; Lee FH; Ahmad N; Pierson TC; Doms RW
    J Virol; 2004 May; 78(10):5476-85. PubMed ID: 15113926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1.
    Nakano Y; Monde K; Terasawa H; Yuan Y; Yusa K; Harada S; Maeda Y
    Virology; 2014 Mar; 452-453():117-24. PubMed ID: 24606688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
    Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
    Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.
    Espy N; Pacheco B; Sodroski J
    Virology; 2017 Aug; 508():90-107. PubMed ID: 28521215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
    Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D
    Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
    LaBranche CC; Hoffman TL; Romano J; Haggarty BS; Edwards TG; Matthews TJ; Doms RW; Hoxie JA
    J Virol; 1999 Dec; 73(12):10310-9. PubMed ID: 10559349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.
    Locher CP; Witt SA; Kassel R; Dowell NL; Fujimura S; Levy JA
    J Gen Virol; 2005 Apr; 86(Pt 4):1171-1179. PubMed ID: 15784911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.
    Alsahafi N; Debbeche O; Sodroski J; Finzi A
    PLoS One; 2015; 10(4):e0122111. PubMed ID: 25849367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
    Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
    J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    Ly A; Stamatatos L
    J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.